CTLA4 and neoplasm: This consistency can be biologically explained by the complementary mechanisms of dual immune checkpoint blockade: PD-1/PD-L1 inhibition restores cytotoxic T-cell activity, while CTLA-4 inhibition enhances T-cell priming and broadens the tumor-infiltrating lymphocyte repertoire.